Canada: Footnotes Relating To: The IP Year 2008 In Review: Patents (Part 1 of 3)

The IP Year 2008 In Review: Patents (Part 1)

The IP Year 2008 In Review: Trademarks (Part 2)

The IP Year 2008 In Review: Copyrights (Part 3)

Footnotes

^{1 MONDAQ (http://www.mondaq.com/) awarded Fasken Martineau's The IP Year 2007 In Review the most popular Canadian article on its site in February, 2008. See http://www.mondaq.com/content/awards.asp?id=0539E265-6379-41AB-B278-66CBB5FF3769.}

^{2 http://laws.justice.gc.ca/en/P-4/SOR-96-423/index.html}

^{3 http://www.cipo.ic.gc.ca/epic/site/cipointernet-internetopic.nsf/en/h_wr00030e.html#nov27}

^{4 Patented Medicines (Notice of Compliance) Regulations (http://laws.justice.gc.ca/en/showtdm/cr/SOR-93-133)}

^{5 http://www.cipo.ic.gc.ca/epic/site/cipointernet-internetopic.nsf/en/h_wr00030e.html#sept29}

^{6 http://www.wipo.int/pct-safe/en/}

^{7 http://www.wipo.int/pct-safe/en/certificates.htm}

^{8 https://strategis.ic.gc.ca/cgi-bin/allsites/registration/mainScreen.cgi}

^{9http://www.wipo.int/pct/guide/en/gdvol1/annexes/annexc/ax_c_ca.pdf}

^{10 http://www.cipo.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr01221.html. For a more detailed review, please see the Fasken Martineau practice notice at http://www.fasken.com/Publications/Detail.aspx?publication=4347.}

^{11 http://www.aipla.org/Content/ContentGroups/About_AIPLA1/AIPLA_Reports/20084/bilski.pdf . For a more detailed review, please see the Fasken Martineau practice notice at http://www.fasken.com/ip_bulletin_nov2008/}

^{12 See The IP Year 2007 in Review http://www.fasken.com/ip_the_year_2007_in_review/ . Briefly, the New Rules issued by the USPTO on August 1st 2007 were crafted to significantly limit the number of continuation applications, continuation-in-part applications and requests for continued examination (RCEs) that could be filed by an applicant. The New Rules were also designed to strongly discourage applicants from filing more than five independent claims or more than 25 total claims.}

^{13 2008 FC 712.}

^{14 2008 FCA 35.}

^{15 See IP Year 2006 in Review http://www.fasken.com/publications/detail.aspx?publication=2694 .}

^{16 2008 FC 608}

^{17 Pfizer Canada Inc. v. Canada (Health), 2008 FCA 108; Glaxosmithkline Inc. v. Pharmascience Inc., 2008 FC 593; and Apotex Inc. v. Sanofi Synthelabo Canada Inc., 2008 SCC 61}

^{18 See The IP Year 2006 in Reviewhttp://www.fasken.com/publications/detail.aspx?publication=2694 .}

^{19 See note 17.}

^{20 See note 17.}

^{21 See note 17.}

^{22 2008 CAF 90.}

^{23 See The IP Year 2007 in Review http://www.fasken.com/ip_the_year_2007_in_review/.}

^{24 See The IP Year 2006 in Review and IP Year 2007 in Reviewhttp://www.fasken.com/publications/detail.aspx?publication=2694 ; http://www.fasken.com/ip_the_year_2007_in_review/}.

^{25 See The IP Year 2007 in Review http://www.fasken.com/ip_the_year_2007_in_review/.}

^{26 2008 FCA 256}

^{27 2008 FC 587.}

^{28 2008 FC 538.}

^{29 2008 FC 1185}

^{30 2008 FC 950.}

^{31 [2008] 1 F.C.R. 529.}

^{32 See our IP 2006 Year in Review http://www.fasken.com/publications/detail.aspx?publication=2694.}

^{33 2008 FCA 244.}

^{34 2008 FC 744}

^{35 2008 FC 825.}

^{36 See The IP Year 2007 in Review http://www.fasken.com/ip_the_year_2007_in_review/.}

^{37 2008 FC 552}

^{38 2008 FCA 81.}

^{39 2007 FC 898.}

^{40 See The IP Year 2007 in Review http://www.fasken.com/ip_the_year_2007_in_review /.}

^{41 2008 FCA 138.}

^{42 Sanofi-Aventis Canada Inc. v. Laboratoire Riva Inc., 2008 FC 291; and Solvay Pharma Inc v. Apotex Inc., 2008 FC 308.}

^{43 2006 FCA 229. See The IP Year 2006 in Review http://www.fasken.com/publications/detail.aspx?publication=2694.}

^{44 2006 FCA 357. See The IP Year 2006 in Review http://www.fasken.com/publications/detail.aspx?publication=2694.}

^{45 See note 42.}

^{46 2008 FC 840.}

^{47 [2002] 2 S.C.R. 522}

^{48 See note 2.}

^{49 http://www.cipo.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr01383.html}

^{50 http://www.cipo.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr01467.html.}

^{51 See note 49.}

^{52 http://www.cipo.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr00347.html.}

www.fasken.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.